Cancer Research  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 42, 5015-5017, December 1, 1982]
© 1982 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Herrick, D. J.
Right arrow Articles by Kufe, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Herrick, D. J.
Right arrow Articles by Kufe, D. W.

Effect of Methotrexate on Incorporation and Excision of 5-Fluorouracil Residues in Human Breast Carcinoma DNA1

David J. Herrick, Pierre P. Major2 and Donald W. Kufe3

Division of Medicine, Sidney Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115

We have demonstrated recently that 5-fluorouracil (FUra) residues incorporate in eukaryotic DNA. In the present study, we extend these findings and monitor the effect of methotrexate on the formation of FUra DNA. The results demonstrate that methotrexate treatment has little effect on the incorporation of FUra or 5-fluorodeoxyuridine in DNA obtained from MCF-7 human breast carcinoma cells. More importantly, we demonstrate that FUra residues are excised from MCF-7 DNA and that methotrexate enhances the excision process. This excision of FUra from eukaryotic DNA may contribute to the cytotoxicity and mutagenicity of these fluorinated pyrimidines.

1 This investigation was supported by USPHS Grants CA-28488 and CA-19589 awarded by the National Cancer Institute, Department of Health and Human Services.

2 Fellow of the Medical Research Council of Canada.

3 Recipient of an American Cancer Society Jr. Faculty Research Award. To whom requests for reprints should be addressed, at the Sidney Farber Cancer Institute, 44 Binney Street, Boston, Mass. 02115.

Received 7/12/82. Accepted 9/ 9/82.




This article has been cited by other articles:


Home page
Cancer Res.Home page
M. Meyers, M. W. Wagner, H.-S. Hwang, T. J. Kinsella, and D. A. Boothman
Role of the hMLH1 DNA Mismatch Repair Protein in Fluoropyrimidine-mediated Cell Death and Cell Cycle Responses
Cancer Res., July 1, 2001; 61(13): 5193 - 5201.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1982 by the American Association for Cancer Research.